Heiss 2010.

Methods	Randomised controlled open‐label phase II/III trial
Participants	258 patients with malignant ascites due to epithelial cancer (ovarian cancer n = 129)
Interventions	Intraperitoneal trifunctional antibody (EpCAM) + paracentesis vs paracentesis
Outcomes	Survival (puncture‐free survival/overall survival) Immune responses (HAMA) Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information about the sequence generation process insufficient to permit judgement of ‘low risk’ or ‘high risk’
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	High risk	Reason for missing outcome data likely to be related to true outcome, with imbalance in numbers or reasons for missing data across intervention groups
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Low risk	No other sources of bias detected